Noxafil (posaconazole) / Merck (MSD), Ligand 
Welcome,         Profile    Billing    Logout  

47 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Noxafil (posaconazole) / Merck (MSD)
2015-002703-28: Exploring how the tablet Noxafil reacts in the human body after oral intake Onderzoeken hoe de tablet Noxafil reageert in het menselijk lichaam na orale inname

Ongoing
4
5
Europe
Noxafil, Tablet, Noxafil Tablet 100 mg
KU Leuven - Drug Delivery & Disposition, KU Leuven
• Administering one tablet of Noxafil with a glass of 240 ml of water• Administering four tablets of Noxafil with a glass of 240 ml of water• Administering one tablet of Noxafil with a glass of 240 ml of water, prior to the intake of 400 ml Ensure plus (liquid meal)• Administering four tablets of Noxafil with a glass of 240 ml of water, prior to the intake of 400 ml Ensure plus (liquid meal) • Toediening van 1 tablet in met 240 ml plat water• Toediening van 4 tabletten met 240 ml plat water• Toediening van 1 tablet met 240 ml water, voorafgegaan door inname van 400 ml vloeibare voeding• Toediening van 4 tabletten met 240 ml water, voorafgegaan door inname van 400 ml vloeibare voeding, Healthy volunteers (18-40 years) Gezonde vrijwilligers (18-40 jaar), Body processes [G] - Physiological processes [G07]
 
 
2008-007712-14: Monitoring of serum concentrations of posaconazole given as prophylaxis or therapy.

Ongoing
4
40
Europe
Noxafil, Noxafil
Erasme Hospital
fungal infection
 
 
2010-020953-14: Effects of posaconazole and voriconazole on the pharmacokinetics and pharmacodynamics of sublingual buprenorphine: A three-phase double-blind cross-over study in healthy subjects.

Ongoing
4
12
Europe
J02AC04, J02AC03, Temgesic, Noxafil, Vfend, Temgesic, Noxafil, Vfend
Derartment of Anaesthesiology and Intensive Care, Turku University Hospital
- healty volunteer subjects- The study is aimed to examine the possible interactions of low-dose sublingual buprenorphine with posaconazole and voriconazole.
 
 
2015-003940-38: Study of posaconazole blood levels comparing two different oral presentations, a syrup and a solid tablet, in patients with leukaemia at a high risk of fungal infections Estudio de niveles de posaconazol en sangre comparando dos presentaciones del fármaco, una en jarabe y otra en tabletas, en pacientes con leucemia con alto riesgo de infecciones fúngicas

Ongoing
4
20
Europe
Oral suspension, Gastro-resistant tablet, Noxafil 40 mg/ml suspensión oral, Noxafil 100 mg comprimidos gastrorresistentes
Fundación Investigación Biomédica Puerta de Hierro, Merck Sharp & Dohme España
Invasive Mycoses Micosis invasoras, Severe fungal infections Infecciones graves por hongos, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2012-001244-22: Influence of obesity and gastric bypass on medication absorption: pharmacokinetic study Invloed van obesitas en gastric bypass op geneesmiddelenabsorptie: farmacokinetische studie

Ongoing
4
135
Europe
Theophylline, fenofibrate, Posaconazole, levonorgestrel and ethinyl estradiol, Ferrous sulphate, Theophyllin, Xanthium 200 mg capsules, Lipanthyl 67 Micronised, Noxafil 40mg/ml suspension, Microgynon 30, Xanthium 200 mg capsules, Lipanthyl 67 Micronised, Noxafil 40mg/ml suspension, Microgynon 30
KU Leuven - Centre for Pharmacotherapy, KU Leuven
Obese volunteers and volunteers with a Roux-en-Y gastric bypass (RYGB) Obese vrijwilligers en vrijwilligers met een Roux-en-Y gastric bypass (RYGB)
 
 
2016-001223-31: Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole tablet Prophylaxis

Ongoing
4
150
Europe
Noxafil Gastro resistant tablets, Tablet, Noxafil®
King's College Hospital NHS Foundation Trust, Merck Sharp & Dohme Limited (MSD).
Aplastic Anaemia, Myelodysplastic syndromes, Acute Myeloid Leukaemia undergoing immunosuppression therapy, high dose chemotherapy or reduced intensity stem cell transplantation, Fungal infection as a result of immunosuppressive therapy, chemotherapy or stem cell transplantation., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2017-003270-14: Prevention of influenza-associated aspergillosis in critically ill patients with Posaconazole

Ongoing
4
110
Europe
Concentrate for solution for infusion, Noxafil
UZ Leuven, Radboud University Medical Center, MSD, Merck Sharp & Dohme Ltd
invasive aspergillosis in critically ill patients with influenza pneumonia, aspergillosis as a surinfection of severe influenza, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
ChiCTR1900026294: Study for serum concentration of posaconazole oral suspension for prevention of invasive fungal infection

Recruiting
4
74
 
oral posaconazole 5ml, tid
hematology department of The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Chinese medical association
invasive fungal infection
 
 
ChiCTR1900027069: Therapeutic drug mornitoring of posaconazole oral suspension in patients with liver failure or multiple organ (including liver) failure and optimization of its dosage regimen

Recruiting
4
100
 
posaconazole oral suspension
The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi 'an Jiaotong University, Self-raising
Fungal disease
 
 
ChiCTR2100045800: Analysis and discussion of the factors affecting the blood concentration of posaconazole in patients with hematological malignancies

Recruiting
4
180
 
Posaconazole oral suspension ;Posaconazole suspension in combination with other drugs
The First Hospital of Hebei Medical University; The First Hospital of Hebei Medical University, 1. Hospital Pharmacy Special Research Project of Hebei Pharmaceutical Society 2. Scientific Research Fund Project of Hebei Provincial Health and Family Planning Commission
Fungal disease
 
 
2019-001585-15: PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia Etude d’allocation génétique de la prophylaxie antifongique chez les patients traités pour une leucémie aiguë myéloïde

Ongoing
4
105
Europe
Solution for infusion, Powder for solution for infusion, Capsule, Tablet, Noxafil, Diflucan
Centre Hospitalier Universitaire Vaudois, Swiss National Science Foundation
Invasive mold infections leucémie aigue myéloïde, Invasive mold infections leucémie aigue myéloïde, Not possible to specify
 
 
ChiCTR2100047646: Preliminary study of caspofungin sequential posaconazole in prevention of invasive fungal infection in high-risk liver transplant recipients

Not yet recruiting
4
180
 
Treated with Caspofungin ;Treated with Caspofungin and posaconazole
The Third Affiliated Hospital of Sun Yat-sen University; The Third Affiliated Hospital of Sun Yat-sen University, Guangdong clinical drug research fund -- Fungi special fund
Invasive fungal infection after liver transplantation
 
 
ChiCTR2100054356: Clinical Efficacy of Low-Dose Venetoclax Combinated with Posaconazole in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments Guided by Venetoclax Blood Concentration

Not yet recruiting
4
60
 
oral venetoclax 100mg/d combined with posaconazole200mg tid ;oral venetoclax 400mg/d
Chengdu Third People's Hospital; Chengdu Third People's Hospital, Personal research funds
acute myeloid leukemia
 
 
2017-001433-74: Screening Anti-Fungal Exposure in Intensive Care Units – The French Cohort

Completed
4
40
Europe
Powder for concentrate for dispersion for infusion, Powder for solution for infusion, AmBisome Liposomal Amphotericin B 50mg Powder for Concentrate for Dispersion for Infusion., ECALTA 100 mg powder for concentrate for solution for infusion, CANCIDAS 50 mg powder for concentrate for solution for infusion, Diflucan 150 mg hard capsules, CRESEMBA 200 mg powder for concentrate for solution for infusion, Mycamine 50 mg powder for solution for infusion, Noxafil® 300 mg concentrate for solution for infusion, Voriconazole 200 mg powder for solution for infusion
CHU de NIMES, CHU NIMES
The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents, The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents, Not possible to specify
 
 
ChiCTR2200059472: The effect of GVHD prophylaxis regimens with concomitant posaconazole enteric-coated tablets in recipients with allogeneic stem cell transplantation

Recruiting
4
30
 
The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, MSD INVESTMENT (CHINA) CO., LTD
hematological disease
 
 
POPULAR, NCT03717623: Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

Recruiting
4
100
RoW
Posaconazole pharmacokinetics, Blood sampling
Melbourne Health, Merck Sharp & Dohme LLC
Posaconazole, Pharmacokinetics, Invasive Candidiases, Invasive Aspergillosis, Invasive Mycosis, Fungal Infection, Prophylaxis
12/23
12/23
ChiCTR2200056400: PK/PD assessment of posaconazole enteric-coated tablets in liver transplantation patients in intensive care unit

Not yet recruiting
4
300
 
None
The First Affiliated Hospital of Xi’an Jiaotong University; The First Affiliated Hospital of Xi’an Jiaotong University, MSD INVESTMENT (CHINA) CO., LTD
liver transplantation
 
 
ChiCTR2200056192: Primary antifungal prophylaxis of posaconazole and caspofungin in hematopoietic stem cell transplantation (HSCT) for thalassemia major

Not yet recruiting
4
522
 
Capofungin would be used from the beginning of pretreatment until neutrophils implanted, and Posaconazole would be prophylaxis with neutrophils until 90 days after HSCT. ;Fluconazole would be used from the beginning of pretreatment until neutrophils implanted，and Posaconazle would be prophylaxis with neutrophils until 90 days after HSCT.
Guangzhou Women and Children's Medical Center, Guangzhou; Guangzhou Women and Children's Medical Center, Guangzhou, China., Hospital clinical research cultivation project
Hematopoietic stem cell transplantation recipients with severe thalassemia
 
 
ChiCTR2200064677: Efficacy and safety of posaconazole for the prevention of invasive fungal disease in childhood acute leukemia

Not yet recruiting
4
75
 
Posaconazole
Beijing Children's Hospital, Capital Medical University; Beijing Children's Hospital, Capital Medical University, Self-raised
Invasive fungal disease
 
 
ChiCTR2200063000: Therapeutic drug monitoring of posaconazole enteric-coated tablets in patients with liver failure or multiple organ (including liver) failure

Not yet recruiting
4
20
 
Posconazole
The First Affiliated Hospital of Medical College; The First Affiliated Hospital of Medical College, MSD China Holding CO., Ltd.
Fungal infection
 
 
NCT04966585: Pilot Study of Posaconazole in Crohn's Disease

Recruiting
4
24
US
Posaconazole Delayed Release Oral Tablet, Noxafil, Matching Placebo Tablet
Cedars-Sinai Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Crohn Disease, CARD9 S12N Risk Allele
12/24
12/25
2010-020832-20: P06356

Ongoing
3
96
Europe
SCH 56592 (POSACONAZOLE) Solution for Injection, 18 mg/mL, SCH 56592,
Schering-Plough Research Institute, a Division of Schering Corporation - for Global trials, Schering-Plough Research Institute
This study is going to be conducted in heathy volunteers.
 
 
2018-000972-14: Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole alone in non- or mildly- immunocompromised patients with Chronic Pulmonary Aspergillosis: a prospective, randomized, single blind study, (single aspergilloma excluded).

Not yet recruiting
3
224
Europe
Ambisome®, Sporanox®, Vfend®, NOXAFIL, Powder for solution for infusion, Capsule, Tablet, Ambisome®, Sporanox®, Vfend®, NOXAFIL
CHU DE POITIERS, DGOS, JASSEN, MSD-MERCK, PFIZER, ELIVIE, SOS-Oxygen, VIVISOL, ORHE PHARMA
Chronic Pulmonary Aspergillosis, Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]
 
 
ReSPECT, NCT04368559 / 2017-004981-85: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
3
600
Europe, Canada, US, RoW
Rezafungin for Injection, Intravenous antifungal therapy, Posaconazole, Noxafil, Fluconazole, Generic Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Bactrim, Septra, Intravenous Placebo, Placebo Infusion, Oral Placebo, encapsulated cellulose
Mundipharma Research Limited
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
12/25
12/25
IA-DUET, NCT04876716 / 2020-000627-40: Azole-echinocandin Combination Therapy for Invasive Aspergillosis

Terminated
3
66
Europe
Azole, Voriconazole, isavuconazole, posaconazole, Anidulafungin, Ecalta
Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Stichting Hemato-Oncologie voor Volwassenen Nederland
Invasive Aspergillosis
05/24
05/24
2019-004511-31: Prospective validation and clinical evaluation of a new posaconazole dosingregimen for children and adolescents with cystic fibrosis and Aspergillus infection.

Ongoing
2/3
135
Europe
Noxafil - oral suspension 40 mg/ml, Noxafil 100 mg, [NA], [na], Oral suspension, Gastro-resistant tablet, Noxafil - oral suspension 40 mg/ml, Noxafil 100 mg
Bambino Gesù Children's Hospital, IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA, Innovative Medicines Initiative 2, European Union’s Horizon 2020
Cystic Fibrosis and Aspergillus Infection, Aspergillus infection in people with cystic fibrosis, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
cASPerCF, NCT04966234 / 2019-004511-31: A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection

Recruiting
2/3
135
Europe, RoW
Posaconazole 100 MG [Noxafil], gastro-resistant tablets Noxafil® 100 mg, Posaconazole 40 MG/ML, 105 ml Noxafil® 40 mg/ml oral suspension
Bambino Gesù Hospital and Research Institute, University of Exeter, Radboud University, Consorzio per Valutazioni Biologiche e Farmacologiche
Cystic Fibrosis, Aspergillosis
04/23
11/23
2018-002579-16: Measurement of the posaconazole concentration in exhaled breath in CF patients after a single dose posaconazole to correlate to the concentration in blood and saliva.

Ongoing
2
12
Europe
Tablet, Noxafil®
Karolinska University Hospital, Stockholm CF center, Karolinska University Hospital, Stockholm CF center
Cystic Fibrosis (CF) is the most common life–limiting autosomal recessive disease among people of European heritage. The condition is a result of a mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene on chromosome seven, which encodes a chloride channel. In the lung defective channel activity leads to thick, viscous secretion and impaired mucociliary clearance. This causes trapping of mucus, colonization with bacteria and fungi, and a persistent inflammatory response., In CF, the mucus is thicker and thinner than normally. It is difficult to cough up and it affects the breathing. Some bacteria benefit particularly well in the mucus and causes respiratory infections., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05468372: Amphotericin Versus Posaconazole for Pulmonary Mucormycosis

Recruiting
2
30
RoW
Posaconazole 600 mg followed by posaconazole 300 mg once daily, In the experimental arm, the first seven days of posaconazole will be overlapped with liposomal amphotericin B 5 mg/kg body weight intravenous infusion (similar to the active comparator arm), Liposomal Amphotericin B, LAMB
Postgraduate Institute of Medical Education and Research
Mucormycosis; Pulmonary (Etiology)
12/23
06/24
MK-5592-104, NCT04218851 / 2019-002267-10: Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA)

Completed
2
31
Europe, US, RoW
Posaconazole IV, MK-5592, SCH 056592, Noxafil®, Posaconazole PFS, Posaconazole tablet
Merck Sharp & Dohme LLC
Invasive Aspergillosis
12/23
12/23
MK-5592-127, NCT04665037 / 2019-003842-34: Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection

Recruiting
2
40
Europe, US, RoW
Posaconazole IV 6 mg/kg, MK-5592, NOXAFIL®, SCH56592, Posaconazole PFS 6 mg/kg
Merck Sharp & Dohme LLC
Invasive Fungal Infection
12/25
12/25
BGB-11417-103, NCT04771130: A Study of BGB-11417 in Participants With Myeloid Malignancies

Recruiting
1b/2
260
Europe, US, RoW
BGB-11417, Sonrotoclax, Azacitidine, Posaconazole
BeiGene
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
12/23
08/25
NCT04752163: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Completed
1/2
17
US
DS-1594b, Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, Onureg, U-18496, Vidaza, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Leucovorin, Folinic acid, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Posaconazole, Noxafil, SCH 56592, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vincristine, Leurocristine, VCR, Vincrystine, Voriconazole, Vfend
M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
11/23
11/23
ACTRN12617001219370: Comparative assessment of the absorption of a generic formulation of 40 mg/mL posaconazole oral suspension against the innovator posaconazole oral suspension conducted under fed conditions in healthy male & female volunteers

Not yet recruiting
1
36
 
Zenith Technology Corp Ltd, Douglas Pharmaceuticals Ltd
Fungal infections
 
 
ACTRN12611000364976: Pharmacokinetics and Safety of Solid Oral Posaconazole(SCH 56592) in Subjects at High Risk for Invasive Fungal Infections

Not yet recruiting
1
160
 
Schering-Plough Pty limited, Schering-Plough Pty limited
High Risk for Invasive Fungal Infection due to: - Expected neutropenia (low white blood cell count) due to chemotherapy for Acute Myelogenous Leukaemia (AML) or Myelodysplastic Syndrome (MDS), High Risk for Invasive Fungal Infection due to: - Hematopoietic stem cell transplant (HSCT) recipients undergoing treatment for graft-versus-host disease (GVHD)
 
 
NCT03763396: Azoles Targeting Recurrent High Grade Gliomas

Not yet recruiting
1
30
Canada
Ketoconazole (KCZ), Posaconazole (PCZ)
University Health Network, Toronto
Brain Tumor, Recurrent, Cancer, Advanced, Glioma of Brain
06/25
06/27
NCT04825275: Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial

Recruiting
1
10
US
Posaconazole Pill, Noxafil
Milton S. Hershey Medical Center, National Cancer Institute (NCI)
Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult
12/24
01/25
ChiCTR-ONC-13003626: To establish and evaluate the diagnosis and therapy pathway of cutaneous and subcutaneous mycosis

Completed
N/A
500
 
InterventionIntervention: the patients infected Trichophyton were treated by oral terbinafine, while those infected Microsporum treated by oral itraconazole ;first， itraconazole 200-400mg/d for 3-6 months ;terbinafine 250mg/d for 6-16 weeks;itraconazole 200mg/d for 12 weeks or 400mg/d×7d and interval 21 days for one plus,two-three pluses for fingernail onychomycosis;three-four pluses for toenail;fluconazole 150mg/week，ten-twelve weeks for fingernail onychomycosis and 16-18 weeks for toenail ;itraconazole 200-400mg/d for 3-6 months;or terbinafine 250-500mg/d for 3-6 months.The severe cases were given amphotericin B for one-two months followed by itraconazole or terbinafine. ;first ,amphotericin B for the severe cases from 1mg/d to 0.6-0.8mg//kg/d,for 3 months ,the total dose 25-50mg/kg followed by itraconazole 200-400mg/d for 6 months.itraconazole 200-400mg/d for the mild cases ,the course 3-6 months; or posaconazole 400-800mg/d for 3-6 months. ;itraconazole 200mg/d or fluconazole 150mg/d for one week combined topical drug every month for 6 months;for the cases not controlled diabetes,oral zoles for 2 weeks every month for 6 months combined topical agents.
Institute of Dermatology, Chinese Academy of Medical Sciences; Institute of Dermatology, Chinese Academy of Medical Sciences, Science and Technology Agency of Jiangsu Province
cutaneous and subcutaneous mycosis
 
 
NCT03421366: Modified Release Posaconazole in Patients With Cystic Fibrosis

Recruiting
N/A
20
RoW
Posaconazole
Bayside Health
Cystic Fibrosis
02/21
02/21
BIMI, NCT04720144: Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis

Recruiting
N/A
300
Europe
Centre Hospitalier Universitaire Vaudois
Invasive Mold Infections, Breakthrough Invasive Mold Infections, Hematologic Malignancy, Hematologic Diseases
09/22
09/22
ChiCTR2300068601: Construction of individual medication model of posaconazole in patients with hematopathy based on sparse plasma concentration

Not yet recruiting
N/A
50
 
Measure the plasma concentration of posaconazole
Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University; The Third Xiangya Hospital, Central South University, Sustentation Funds
Malignant hematopathy
 
 
Posa-Pk, NCT03796533: Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity

Recruiting
N/A
120
Europe
Posaconazole, PCZ
Hospices Civils de Lyon
Leukemia, Myeloid, Acute
04/23
04/23
ChiCTR2200059961: Drug-Drug Interactions between Posaconazole and ruxolitinib in patients with hematological diseases

Not yet recruiting
N/A
12
 
5mg ruxolitinib orally
Chinese PLA General Hospital; Chinese PLA General Hospital, Sub-topics of Major Projects of Ministry of Science and Technology (2018ZX09201018-022)
Hematological malignancies
 
 
ChiCTR2200059843: Computer simulation model based on physiologically based pharmacokinetic to guide the individualized drug administration strategy of posaconazole in pediatric

Not yet recruiting
N/A
278
 
Before the 7th day of medication, blood samples were collected for the determination of posaconazole concentration ;Before the 7th day of medication, blood samples were collected for the determination of posaconazole and cyclosporine concentrations ;PBPK model prediction were used to guide the individual prescription of Posaconazole ;Before the 7th day of medication, blood samples were collected for the determination of posaconazole concentration ;PBPK model prediction were used to guide the individual prescription of Posaconazole and cyclosporine ;Before the 7th day of medication, blood samples were collected for the determination of posaconazole and cyclosporine concentrations
Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University; Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai Health Commission Clinical Research Fund
Prevention or treatment of invasive fungal disease
 
 
PTX3 AML, NCT03828773: PTX3-targeted Antifungal Prophylaxis

Recruiting
N/A
320
Europe
Posaconazole, Noxafil, Fluconazole, Diflucan
Bochud Pierre-Yves, Swiss National Science Foundation
Candidiasis, Fungal Infection, Acute Myeloid Leukemia, Genetic Predisposition, Aspergillosis
11/25
11/25
POSACOVID, NCT05065658: Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients

Completed
N/A
249
Europe
Posaconazole
Medical University of Graz, Merck Sharp & Dohme LLC
COVID-19 Respiratory Infection, Aspergillosis
08/23
08/23
NCT04725942: Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients

Not yet recruiting
N/A
360
RoW
Oral Posaconazole tablets
Institute of Hematology & Blood Diseases Hospital, Shanxi Bethune Hospital, The Second Hospital of Hebei Medical University, Tianjin Medical University Cancer Institute and Hospital
Pulmonary Fungal Infection
04/23
04/23

Download Options